Verastem (NASDAQ: VSTM) — Perfil da empresa, notícias e dados financeiros
Verastem focuses on developing small molecule therapies for cancer, committed to improving treatment outcomes.
Verastem
Verastem (NASDAQ:VSTM) is a biopharmaceutical company focused on developing and commercializing medicines aimed at the treatment of cancer. Their operations are centered around pioneering small molecule drugs that target critical pathways in the growth and survival of cancer cells. Verastem's projects typically involve conducting clinical trials, engaging in rigorous research and development, and seeking regulatory approvals for their innovative treatments. The company’s objective is to significantly improve outcomes for patients suffering from various forms of cancer by offering new, targeted therapeutic options. Their commitment to advancing cancer treatment is evident in their pursuit of cutting-edge science and their collaboration with healthcare professionals and institutions worldwide.
Resumo
Operações
Produtos e/ou serviços de Verastem
- COPIKTRA (duvelisib) is an oral inhibitor of PI3K, used for treating chronic lymphocytic leukemia, small lymphocytic lymphoma, and follicular lymphoma.
- VS-6766, a RAF/MEK clamp, targets RAS mutation-positive tumors, intended for various solid tumors including lung, colorectal, and melanoma.
- Defactinib is aimed at treating mesothelioma and solid tumors, focusing on inhibiting focal adhesion kinase (FAK) to prevent cancerous cell spread.
- VS-4718 targets cancer stem cells by inhibiting FAK, aimed at overcoming resistance to chemotherapy and preventing cancer recurrence.
- VS-5584, a dual inhibitor of PI3K/mTOR, is in development for treating solid tumors and lymphomas, aiming at disrupting cancer cell growth and survival.
- The Focal Adhesion Kinase (FAK) Inhibition Program focuses on developing treatments for pancreatic and other cancers by targeting the tumor microenvironment.
equipe executiva do Verastem
- Daniel W. PatersonPresident, CEO & Director
- Daniel CalkinsChief Financial Officer
- Michael Glen KauffmanPresident of Development & Director
- Robert A. WeinbergCo-Founder & Chair of Scientific Advisory Board
- Michelle DetwilerCo-Founder
- Lori HorvatExecutive Vice President of Portfolio Strategy & Operations
- Jonathan PachterChief Scientific Officer
- Julissa VianaVice President of Corporate Communications & Investor Relations
- Mark J. WandaSenior VP of Legal & Chief Compliance Officer
- Cathy CarewChief Organizational Effectiveness Officer
Principais indicadores financeiros
Resultados divulgados pela Verastem, em USD.
- Cap. de mercado
- 1,2 bi
- Receita (TTM)
- 87,5 mi
- P/L
- —
- LPA (diluído, TTM)
- -2.5
- Dividend yield
- —
- Margem de lucro
- -231.6%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 30,9 mi | -170,1 mi | -209,5 mi | |
| 10 mi | -115 mi | -130,6 mi | |
| 0 | -92,1 mi | -87,4 mi | |
| 2,6 mi | -72,9 mi | -73,8 mi |